Particle.news

Fibromyalgia Research Advances Amid Persistent Challenges in Diagnosis and Care

Ongoing studies into neuroinflammation and SGK1 modulation offer hope for targeted therapies, while patients continue to face diagnostic delays and societal stigma.

Overview

  • Fibromyalgia affects 2–4% of the global population, with a 9:1 female-to-male ratio, and lacks a definitive diagnostic test or cure.
  • Recent research highlights neuroinflammation and SGK1-targeting molecules as potential breakthroughs in understanding and treating the condition.
  • In Spain, over 275,800 cases are officially diagnosed, but experts estimate nearly one million people may be affected, highlighting significant underdiagnosis.
  • Patients report severe impacts on quality of life, including chronic pain, fatigue, depression, and social stigma, often compounded by delayed diagnoses.
  • Multimodal treatment approaches combining education, supervised exercise, psychological support, and personalized pharmacological therapies remain the cornerstone of care.